Effect of Intravenous Zoledronic Acid on Tibiofemoral Cartilage Volume Among Patients With Knee Osteoarthritis With Bone Marrow Lesions

Abstract

IMPORTANCE A proof-of-principle study suggested that intravenous zoledronic acid may reduce knee pain and the size of bone marrow lesions in people with knee osteoarthritis, but data from large trials are lacking.OBJECTIVE To determine the effects of intravenous zoledronic acid on knee cartilage volume loss in patients with symptomatic knee osteoarthritis and bone marrow lesions. DESIGN, SETTING, AND PARTICIPANTSA 24-month multicenter, double-blind placebo-controlled randomized clinical trial conducted at 4 sites in Australia (1 research center and 3 hospitals). Adults aged 50 years or older with symptomatic knee osteoarthritis and subchondral bone marrow lesions detected by magnetic resonance imaging (MRI) were enrolled from November 2013 through September 2015. The final date of follow-up was October 9, 2017.INTERVENTIONS Intravenous infusion with either 5 mg of zoledronic acid in a 100-mL saline solution (n = 113) or a placebo saline solution (n = 110) at baseline and 12 months. MAIN OUTCOMES AND MEASURESThe primary outcome was absolute change in tibiofemoral cartilage volume assessed using MRI over 24 months (the minimum clinically important difference [MCID] has not been established). Three prespecified secondary outcomes were change in knee pain assessed by a visual analog scale (0 [no pain] to 100 [unbearable pain]; MCID, 15) and the Western Ontario and McMaster Universities Osteoarthritis Index (0 [no pain] to 500 [unbearable pain]; MCID, 75) over 3, 6, 12, 18, and 24 months and change in bone marrow lesion size over 6 and 24 months (the MCID has not been established). RESULTSOf 223 participants enrolled (mean age, 62.0 years [SD, 8.0 years]; 52% were female), 190 (85%) completed the trial. Change in tibiofemoral cartilage volume was not significantly different between the zoledronic acid group and the placebo group over 24 months (−878 mm 3 vs −919 mm 3 ; between-group difference, 41 mm 3 [95% CI, −79 to 161 mm 3 ]; P = .50). No significant between-group differences were found for any of the prespecified secondary outcomes, including changes in knee pain assessed by a visual analog scale (−11.5 in the zoledronic acid group vs −16.8 in the placebo group; between-group difference, 5.2 [95% CI, −2.3 to 12.8]; P = .17), changes in knee pain assessed by the Western Ontario and McMaster Universities Osteoarthritis Index (−37.5 vs −58.0, respectively; between-group difference, 20.5 [95% CI, −11.2 to 52.2]; P = .21), and changes in bone marrow lesion size (−33 mm 2 vs −6 mm 2 ; between-group difference, −27 mm 2 [95% CI, −127 to 73 mm 2 ]; P = .60) over 24 months. Adverse events were more common with zoledronic acid than with placebo (96% vs 83%, respectively) and consisted mainly of acute reactions (defined as symptoms within 3 days of administration of infusion; 87% vs 56%).CONCLUSIONS AND RELEVANCE Among patients with symptomatic knee osteoarthritis and bone marrow lesions, yearly zoledronic acid infusions, compared with placebo, did not significantly reduce cartilage volume loss over 24 months. These finding...

Subchondral Bone Remodeling: A Therapeutic Target for Osteoarthritis

“…For example, alendronate and zoledronate were reported to relieve subchondral bone pathological changes, thus effectively protecting the articular cartilage in OA animal models (Zhu et al, 2013 ; Lampropoulou-Adamidou et al, 2014 ). Clinically, the therapeutic effect of BPs for OA patients is controversial (Laslett et al, 2012 ; Cai et al, 2020 ). One up-to-date meta-analysis of randomized controlled trials involving 3,013 patients showed that BPs did not significantly improve OA in pain and structural and functional aspects compared to placebo (Vaysbrot et al, 2018 ).…”

New Trends in Pharmacological Treatments for Osteoarthritis

“…BMLs detected by MRI represented areas of high bone turnover and active bone remodeling, and bisphosphonates might be beneficial for patients with high metabolic activity (Kuttapitiya et al, 2017). However, recently, a 24-month multicenter, double-blind placebo-controlled randomized clinical trial assessed the effects of twice-yearly intravenous Zoledronic Acid for 24 months on CVL in patients with symptomatic knee OA and BMLs (Cai et al, 2020). The results showed that Zoledronic Acid did not significantly reduce cartilage volume loss, relieve pain, or improve BMLs.…”

Imaging and Biochemical Markers for Osteoarthritis

“…Some of these markers can play an important role in clinical trials to explore an individual-patient-based approach to test DMOADs. For example, our CurKOA trial tested Curcuma longa extract in knee OA patients with ultrasonography-defined effusion–synovitis (local inflammatory phenotype), and the ZAP2 trial assessed the effects of intravenous zoledronic acid in knee OA patients with subchondral bone marrow lesions (BML) detected by MRI (subchondral bone pathology phenotype) [ 29 , 30 ]. Similarly, encouraging results from a post hoc analysis of the CANTOS trial consisting of a population with elevated high sensitivity C-reactive protein (hsCRP) levels further support the exploration of the personalized medicine approach in OA [ 31 ].…”